Friday 16 October 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.
1.84
0.07
−3.66%
Follow ALEC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (385.11%) | (238.85%) | (181.56%) | (121.98%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
2 | 1 | 1 | 3 | |
| (42.15%) | (38.69%) | (37.54%) | (25.31%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(76.15%) | (68.13%) | (68.79%) | (46.21%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.42) | (1.57) | (1.79) | (1.93) | |
Free Cash Flow |
(158.39) | (173.20) | (184.07) | (197.58) | |
Capital Expenditures |
(0.16) | (0.14) | (0.04) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(91.73%) | (76.41%) | (62.11%) | (55.12%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
715.07% | 582.51% | 584.77% | 198.50% | |
Selling, General and Administrative Expense of Revenue |
297.33% | 257.19% | 256.53% | 80.63% | |
Share Based Compensation of Revenue |
120.92% | 115.19% | 126.67% | 46.38% | |
Operating CF/Net income |
1.34 | 1.38 | 1.29 | 1.83 | |
Depreciation/Fixed assets |
0.57 | 0.50 | 0.31 | 0.14 | |
Capex/Depreciation |
(0.03) | (0.03) | (0.01) | (0.12) | |
Revenue per Share |
0.12 | 0.17 | 0.20 | 0.67 | |
Operating CF per Share |
(1.42) | (1.56) | (1.79) | (1.92) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 |
Columns are period end dates